Health
Novavax COVID-19 vaccine and the US government’s stance on additional doses
The COVID-19 pandemic has brought the world to its knees, and the development and distribution of vaccines have been critical in the fight against the virus. One of the vaccines that has gained widespread attention against the pandemic’s backdrop is the Novavax COVID-19 vaccine. This article provides insight into the Novavax COVID-19 vaccine, how it works, and the US government’s stance on procuring additional doses during the pandemic. Understanding the Novavax COVID-19 Vaccine The Novavax COVID-19 vaccine, also known as NVX-CoV2373, is a protein subunit vaccine developed by the biotechnology company Novavax. Unlike other mRNA vaccine options or viral vector vaccines, the Novavax vaccine employs a different approach. Protein subunit vaccine The Novavax vaccine is a protein subunit vaccine. This means it contains a harmless piece of the virus, in this case, the spike protein of SARS-CoV-2, which causes COVID-19. This spike protein is not infectious but is enough to stimulate an immune response when introduced into the body. Adjuvant To enhance the body’s immune response, Novavax includes an adjuvant called Matrix-M in its vaccine. The adjuvant is a substance that helps boost the body’s immune response to the spike protein, making the vaccine more effective. Certainly, here’s another piece to further understand the Novavax COVID-19 vaccine:
Read More